Is Viking Therapeutics The Best Nash Stock To Buy Now?

Shares of Viking Therapeutics (NASDAQ: VKTX) soared after the biotech announced solid results for its lead candidate. That's because it's aimed at treating non-alcoholic steatohepatitis (NASH), or liver damage caused by excess fat buildup. NASH threatens the lives of around 20 million Americans, and there aren't any effective treatment options yet.Viking Therapeutics probably won't be the first biotech to market a NASH treatment, but it looks like its lead candidate could be best at stopping NASH from occurring in the first place. Let's look at what results for VK2809 could mean for Viking shareholders down the road to see if this is the best NASH stock investors can buy right now.Image source: Getty Images.Continue reading

Topics:  viking therapeutics nasdaq   vktx    americans   vk2809   images   viking therapeutics   viking   nash   buy   results   treatment   candidate   lead   biotech   
BING NEWS:
  • Applied DNA Announces 1-For-20 Reverse Stock Split
    Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be ...
    04/22/2024 - 8:25 am | View Link
  • Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead
    Viking plans to continue dose escalation in current trial meaning further data might not be far ahead, especially if it doses patients for just 4 weeks. Learn more on VKTX stock here.
    04/18/2024 - 9:01 am | View Link
  • Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
    CRISPR Therapeutics ( CRSP -5.29%) and Viking Therapeutics ( VKTX -1.62%) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the ...
    04/9/2024 - 2:59 am | View Link
  • Viking Therapeutics: Future Weight Loss Heavyweight?
    Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735 ...
    04/2/2024 - 12:01 am | View Link
  • Could Viking Therapeutics Stock Be a Millionaire Maker?
    Could Viking Therapeutics stock be a millionaire-maker ... a phase 2b study as a treatment of nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis ...
    04/1/2024 - 10:50 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News